IDXG INTERPACE BIOSCIENCES, INC.
Surgical & Medical Instruments & Apparatus · OTC · SEC CIK 1054102 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-9.7%
TTM net income YoY355.8%
TTM EPS YoY217.6%
Revenue 3-yr CAGR-12.3%
Net income 3-yr CAGR—
Margins
Gross margin65.6%
Operating margin1.6%
Net margin58.1%
FCF margin7.6%
EBITDA margin3.0%
Returns
ROE179.8%
ROA88.6%
ROIC (approx.)6.2%
Asset turnover1.53x
Leverage & solvency
Liabilities / assets34.1%
Debt / equity0.00x
Current ratio2.06x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.16x
Accruals ratio74.5%
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $38.73M | $46.93M | $40.04M | $31.84M | $8.20M |
| Cost of revenue | $14.60M | $17.00M | $14.98M | $13.61M | $14.31M |
| Gross profit | $24.13M | $29.93M | $25.06M | $18.23M | $18.80M |
| R&D expense | $642,000 | $676,000 | $636,000 | $703,000 | $1.49M |
| SG&A expense | $9.48M | $9.49M | $9.36M | $10.97M | $10.71M |
| Operating income | $4.08M | $8.11M | $3.96M | -$3.62M | -$6.34M |
| Pretax income | $3.77M | $6.95M | $2.28M | -$5.84M | -$7.74M |
| Income tax | -$21.21M | $4,000 | $17,000 | $29,000 | -$705,000 |
| Net income | $24.57M | $6.70M | $1.95M | -$21.96M | -$14.94M |
| EBITDA | $4.51M | $8.41M | $4.98M | -$1.06M | -$962,000 |
| EPS (basic) | 5.55 | 1.42 | 0.45 | -5.18 | -3.61 |
| EPS (diluted) | 0.89 | 0.40 | 0.45 | -5.18 | -3.61 |
| Weighted avg. shares (diluted) | 27.70M | 15.73M | 4.36M | 4.24M | 4.13M |
| Banking | |||||
| Net interest income | — | — | -$112,000 | -$158,000 | -$496,000 |
| Balance sheet | |||||
| Cash & equivalents | $2.50M | $1.46M | $3.50M | $4.83M | $3.31M |
| Receivables | $5.65M | $8.54M | $5.08M | $5.03M | $4.67M |
| Inventory | $1.11M | $1.21M | $1.23M | $1.22M | $825,000 |
| Current assets | $9.90M | $11.77M | $10.42M | $12.15M | $12.17M |
| PP&E, net | $1.42M | $1.36M | $790,000 | $480,000 | $317,000 |
| Goodwill | — | — | — | — | $8.43M |
| Intangibles | — | — | — | $861,000 | $2.13M |
| Total assets | $33.84M | $14.79M | $13.12M | $15.98M | $38.43M |
| Current liabilities | $5.10M | $10.62M | $11.44M | $14.28M | $15.68M |
| Short-term debt | — | — | — | $578,000 | $762,000 |
| Long-term debt | — | — | — | $1.85M | $520,000 |
| Total debt | — | — | — | $2.43M | $1.28M |
| Total liabilities | $11.47M | $17.01M | $22.12M | $32.52M | $34.31M |
| Shareholders' equity | $22.36M | -$2.22M | -$55.54M | -$58.09M | -$42.42M |
| Net debt | — | — | — | -$2.40M | -$2.03M |
| Shares outstanding | 885,708 | 4.41M | 4.35M | 4.30M | 4.20M |
| Cash flow statement | |||||
| Operating cash flow | $5.83M | $4.65M | $3.79M | -$7.69M | -$8.72M |
| Capital expenditure | $356,000 | $876,000 | $470,000 | $322,000 | $354,000 |
| Free cash flow | $5.47M | $3.77M | $3.32M | -$8.01M | -$9.07M |
| Investing cash flow | -$356,000 | -$876,000 | -$87,000 | $6.21M | -$315,000 |
| Financing cash flow | -$4.43M | -$5.81M | -$5.03M | $3.00M | $8.98M |
| Depreciation & amortization | $425,000 | $300,000 | $1.03M | $2.56M | $5.37M |
| Stock-based compensation | $35,000 | $291,000 | $630,000 | $1.26M | $1.25M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.